IP Library Granted Patent US 8,604,027
Granted Patent B2
US 8,604,027 · App. 12/772,280 · Granted Dec 10, 2013

Cyclic progestin regimens and kits

Inventors: Gary Sondermann Grubb (Newtown Square, PA); Ginger Dale Constantine (Malvern, PA)
Assignee: Wyeth LLC
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,604,027
App. No.
12/772,280
Granted
Dec 10, 2013
Kind
B2
Abstract

A method of contraception is provided which involves delivery of 21 to 27 consecutive days of a progestin in the absence of an estrogen or other steroidal compound, followed by 1 to 7 days without an effective amount of an active agent. Also described is a pharmaceutically useful kit to facilitate delivery of this regimen.

Claims (44)

1. A method of contraception in a female of child bearing age which comprises administering over a period of 28 consecutive days:

(a) a first phase in which from 21 to 27 daily dosage units of an active agent are administered, each daily dosage unit containing an effective amount of an active agent consisting of a progestin of the formula:

(b) a second phase of from 1 to 7 days wherein no effective amount of said progestin is administered;

wherein said method is performed in the absence of a second steroidal compound.

2. The method according to claim 1 , wherein from 1 to 7 daily dosage units of a pharmaceutically acceptable placebo are delivered in the second phase.

3. The method according to claim 1 , which comprises:

a) a first phase of 21 daily dosage units; and

b) a second phase of 7 daily dosage units of an orally and pharmaceutically acceptable placebo.

4. The method according to claim 1 , which comprises:

a) a first phase of 23 daily dosage units; and

b) a second phase of 5 daily dosage units of an orally and pharmaceutically acceptable placebo.

5. The method according to claim 1 , which comprises:

a) a first phase of 25 daily dosage units; and

b) a second phase of 3 daily dosage units of an orally and pharmaceutically acceptable placebo.

6. The method according to claim 1 , which comprises:

a) a first phase of 27 daily dosage units; and

b) a second phase of 1 daily dosage units of an orally and pharmaceutically acceptable placebo.

7. The method according to claim 1 , wherein said effective amount is between about 0.03 and about 0.6 mg.

8. The method according to claim 7 , wherein said effective amount is between about 0.1 and about 0.5 mg.

9. The method according to claim 8 , wherein said effective amount is about 0.1 mg.

10. The method according to claim 8 , wherein said effective amount is about 0.2 mg.

11. The method according to claim 8 , wherein said effective amount is about 0.3 mg.

12. The method according to claim 1 , which produces complete ovulation inhibition in said female.

13. The method according to claim 1 , which does not rely on cervical mucus thickening of said female.

14. A method of contraception in a female of child bearing age, said method comprising administering over a period of 28 consecutive days:

(a) a first phase in which from 21 to 27 daily dosage units of an active agent are administered, each daily dosage unit containing an effective amount of an active agent consisting of a progestin of the formula:

(b) a second phase of from 1 to 7 days wherein no effective amount of said progestin is administered;

wherein said method is performed in the absence of an estrogen.

15. A method of contraception in a female of child bearing age which consists essentially of administering over a period of 28 consecutive days:

(a) a first phase in which from 21 to 27 daily dosage units of an active agent are administered, each daily dosage unit consisting of an effective amount of Tanaproget;

(b) a second phase of from 1 to 7 days wherein no effective amount of Tanaproget is administered;

wherein said method is performed in the absence of a second steroidal compound.

16. A method of contraception in a female of child bearing age which consists essentially of administering over a period of 28 consecutive days:

(a) a first phase in which from 21 to 27 daily dosage units of an active agent are administered, each daily dosage unit consisting of an effective amount of Tanaproget;

(b) a second phase of from 1 to 7 days wherein no effective amount of Tanaproget is administered;

wherein said method is performed in the absence of an estrogen.

17. A method of contraception in a female of child bearing age which consists of administering over a period of 28 consecutive days:

(a) a first phase in which from 21 to 27 daily dosage units of an active agent are administered, each daily dosage unit consisting of an effective amount of an active agent consisting of Tanaproget;

(b) a second phase of from 1 to 7 days wherein no effective amount of Tanaproget is administered;

wherein said method is performed in the absence of a second steroidal compound.

18. A method of contraception in a female of child bearing age which consists of administering over a period of 28 consecutive days:

(a) a first phase in which from 21 to 27 daily dosage units of an active agent are administered, each daily dosage unit consisting of an effective amount of an active agent consisting of Tanaproget;

(b) a second phase of from 1 to 7 days wherein no effective amount of Tanaproget is administered;

wherein said method is performed in the absence of an estrogen.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 8, 2013
From: GRUBB, GARY SONDERMANN; CONSTANTINE, GINGER DALE
To: WYETH
Reel/Frame 031565/0746 →
CHANGE OF NAME Recorded Nov 8, 2013
From: WYETH
To: WYETH LLC
Reel/Frame 031608/0099 →
Continuity (3)
Continuation 11174592 · Jul 6, 2005
Provisional Application 60586045 · Jul 7, 2004
Related Publication 20100292198A1 · Nov 18, 2010